Article
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 May 2006
de Vries-Sluijs T E M S, van der Eijk A A, Hansen B E, Osterhaus A D M E, de Man R A, van der Ende M E
Abstract excerpt
Prolonged lamivudine therapy has been identified as the major risk for the development of resistance in HBV, with rates of 90% after 4 years of treatment. Tenofovir disoproxil fumarate showed activity against both wild type and lamivudine resistant HBV in HIV-HBV co-infected patients. In order to compare the efficacy of lamivudine/tenofovir treatment we investigated detailed HBV kinetics in 13 HIV-HBV co-infected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.